Core Viewpoint - Qingfeng Biotech has completed a Pre-A round financing of several tens of millions, led by Baiyun Fund, to accelerate the development of AI-driven laboratory automation and expand production capacity [1] Group 1: Company Overview - Qingfeng Biotech, established in 2018, focuses on the R&D, production, and sales of high-end life science automation equipment and related modules, possessing fully independent core technology [2] - The company aims to break the long-standing foreign monopoly in the high-end laboratory automation equipment market, where imported brands hold over 95% market share [2] Group 2: Technological Advancements - The core of Qingfeng's large-scale liquid handling workstation is a flexible 8-channel liquid handling module with non-equidistant dual liquid level detection, crucial for expanding application scenarios [3] - In 2025, Qingfeng successfully won a bid for a large liquid handling workstation project valued at nearly 2 million, marking a significant step in domestic high-end laboratory automation equipment replacement [3] Group 3: Strategic Initiatives - The investment from Baiyun Fund will support Qingfeng in deepening technology transformation and industrial implementation [3] - Qingfeng is leading the establishment of the "Life Science Automation Innovation Center," which has been included in the list of innovation centers in Guangzhou, focusing on key technology R&D and promoting collaborative innovation [4] Group 4: AI and Automation Integration - The integration of AI and automation is seen as a significant advancement, with Qingfeng aiming to develop "self-driving labs" that enhance productivity [5] - The company's self-developed BioFlow AI translates scientists' natural language into executable experimental requirements, while Supervisor AI focuses on data governance and optimization [5] Group 5: Investment Background - Baiyun Fund, established in August 2017 with a registered capital of 200 million, is a private equity investment institution managing over 8.048 billion in assets and has invested in 62 projects [6]

Core Viewpoint - Qingfeng Biotech has completed a multi-million Pre-A round financing, led by Baiyun Fund, to advance its AI+ laboratory automation initiatives, including capacity expansion and the development of AI models [1] Market Status - The laboratory automation market is entering a stable growth phase, with AI becoming a key driver. The global market size is projected to reach approximately $8-8.3 billion in 2024, $9 billion in 2025, and $14-18 billion by 2030, maintaining a compound annual growth rate (CAGR) of 7-9% [2] - In China, the AI-related laboratory market is expected to grow from approximately 15-20 billion RMB in 2024 to 20-25 billion RMB in 2025, and reach 50-60 billion RMB by around 2030, with a CAGR of 15-20% [4] Company Overview - Qingfeng Biotech, established in 2018, focuses on the R&D, production, and sales of life science automation equipment and integrated platforms. The company emphasizes system-level design and platform delivery capabilities rather than just single-device solutions [5] - The OutStanding large-scale automated pipetting workstation integrates high flexibility, modularity, and standardization, supporting multiple life science applications. It has successfully bid for a project valued at nearly 2 million RMB per unit, competing with imported brands [5] AI Integration - Qingfeng Biotech is enhancing its laboratory automation applications by integrating AI capabilities, focusing on the development of BioFlow AI and Supervisor AI models for experimental process management and data-driven optimization [6] - The trend of "AI+ smart laboratories" is evolving from single-point algorithms to core capabilities throughout the entire experimental process, aiming to reduce human error and improve operational efficiency [7] Post-Financing Strategy - The company's development focus is shifting from individual equipment to a systematic construction of "automation platforms + AI capabilities." The financing will be directed towards capacity, algorithms, application centers, and platform capabilities, highlighting the importance of scalable delivery and long-term technological evolution [8]